← Leaderboards
Marc S Sabatine
Brigham And Women'S Hospital
$10,458,271
Attributed
$17,491,532
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–17$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$17,491,532 · 10
By mechanism
R01$11,120,531 · 5
UH3$3,208,055 · 1
RC1$1,991,152 · 2
UH2$1,074,150 · 1
F32$97,644 · 1
Top collaborators
- Saumya Das9 shared
- Robert E Gerszten9 shared
- Raymond Y Kwong9 shared
- Anthony Rosenzweig9 shared
- Steven A. Carr4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Katherine Scovner Ravi$1,177,756
- Jessica L Mega$985,657
- Raymond Y Kwong$3,339,863
- Michael E Davis$12,589,296
- Robert M. Friedlander$14,236,800
Others in their field
Top investigators on “Myocardial Infarction”
- Judith S Hochman · New York University School Of Medicine$121,330,744
- Paul M. Ridker · Brigham And Women'S Hospital$57,742,470
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$57,397,502
- Pamela Susan Douglas · Duke University$51,876,470
- Julie E Buring · Brigham And Women'S Hospital$46,647,558
- Walter N Kernan · Yale University$42,197,025
Research focus
Myocardial InfarctionValidationCohortCardiovascular SystemBaseRisk FactorsPrognosticClinical TrialsBiomarkerCardiacLinkPlasmaGenesPhenotypeMonitorCardiovascular DiseasesSamplingCoronary ArteriosclerosisBiologicalPublic Health RelevanceCardiac MyocytesBlood TestsHigh RiskMorbidity - Disease Rate
Grant awards (36)
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$1,000,000
UH3 · FY2017 · TR
Multi-group collaborative proposal: Diversity and function of prevalent uncharacterized exRNA species from tissue and biofluid$77,805
UH3 · FY2017 · TR
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$1,000,000
UH3 · FY2016 · TR
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$43,250
UH3 · FY2016 · TR
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$1,000,000
UH3 · FY2015 · TR
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$87,000
UH3 · FY2015 · TR
Metabolomic Biomarkers of Early Myocardial Injury$734,748
R01 · FY2014 · HL
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$500,000
UH2 · FY2014 · TR
Optimization of biofluid ex-RNA isolation and characterization.$74,150
UH2 · FY2014 · TR
Metabolomic Biomarkers of Early Myocardial Injury$649,776
R01 · FY2013 · HL
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$500,000
UH2 · FY2013 · TR
Metabolomic Biomarkers of Early Myocardial Injury$763,478
R01 · FY2012 · HL
Discovery & Application of Proteomics-Based Biomarkers of Early Myocardial Injury$737,576
R01 · FY2012 · HL
Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein Biomarkers$441,788
R01 · FY2012 · HL · contact PI
Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease$312,400
R01 · FY2012 · HL · contact PI
Metabolomic Biomarkers of Early Myocardial Injury$758,842
R01 · FY2011 · HL
Discovery & Application of Proteomics-Based Biomarkers of Early Myocardial Injury$750,332
R01 · FY2011 · HL
Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein Biomarkers$445,834
R01 · FY2011 · HL · contact PI
Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease$315,544
R01 · FY2011 · HL · contact PI
Metabolomic Biomarkers of Early Myocardial Injury$805,350
R01 · FY2010 · HL
Discovery & Application of Proteomics-Based Biomarkers of Early Myocardial Injury$721,603
R01 · FY2010 · HL
Biomarkers of Prognosis and Response to Therapy in Acute Coronary Syndromes$498,462
RC1 · FY2010 · HL · contact PI
Genetic Risk Stratification to Identify Individuals for Early Statin Therapy$492,835
RC1 · FY2010 · HL · contact PI
Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein Biomarkers$445,000
R01 · FY2010 · HL · contact PI
Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease$312,950
R01 · FY2010 · HL · contact PI
Discovery & Application of Proteomics-Based Biomarkers of Early Myocardial Injury$738,755
R01 · FY2009 · HL
Biomarkers of Prognosis and Response to Therapy in Acute Coronary Syndromes$500,000
RC1 · FY2009 · HL · contact PI
Genetic Risk Stratification to Identify Individuals for Early Statin Therapy$499,855
RC1 · FY2009 · HL · contact PI
Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein Biomarkers$444,167
R01 · FY2009 · HL · contact PI
Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery Disease$315,138
R01 · FY2009 · HL · contact PI
Genetic Predictors of Outcome in Acute MI$389,250
R01 · FY2005 · HL
Genetic Predictors of Outcome in Acute MI$389,250
R01 · FY2004 · HL
Genetic Predictors of Outcome in Acute MI$389,250
R01 · FY2003 · HL
Genetic Predictors of Outcome in Acute MI$259,500
R01 · FY2002 · HL
Development of Novel Protein Markers of Ischemia$52,084
F32 · FY2002 · HL
Development of Novel Protein Markers of Ischemia$45,560
F32 · FY2001 · HL